Medtronic and Johnson & Johnson present cardiac ablation data at APHRS 2026
At the APHRS 2026 meeting, Medtronic presented registry data for its Sphere-9 catheter and PulseSelect PFA System, while Johnson & Johnson presented studies of its VARIPULSE Pro and investigational OMNYPULSE platforms. Medtronic reported a 1.1% major complication rate in 1,050 AFib patients treated with Sphere-9 and a 0.09% acute major complication rate for PulseSelect in 1,160 patients. Johnson & Johnson reported 100% acute procedural success in 225 VARIPULSE Pro patients and 82.5% freedom from documented atrial arrhythmia recurrence at 12 months for 136 OMNYPULSE patients under stringent monitoring.
Why it matters
The findings add real-world and clinical evidence for competing cardiac ablation systems, with potential implications for adoption across electrophysiology practices. Johnson & Johnson said the results strengthen the clinical evidence supporting its pulsed-field ablation portfolio, while VARIPULSE Pro is not approved in the United States.
Key facts
- 1The APEX registry included 1,050 AFib patients and reported a 1.1% major complication rate with the Sphere-9 catheter. stocktitan.net
- 2The REAL PULSE registry included 1,160 AFib patients treated with the PulseSelect PFA system. stocktitan.net
- 3VARIPURE evaluated 225 patients across 19 European centers and recorded 100% acute procedural success with one primary adverse event, representing 0.4%. gurufocus.com
- 4Omny-IRE evaluated 136 patients, with 82.5% free from documented atrial fibrillation, atrial flutter or atrial tachycardia recurrence at 12 months under stringent monitoring. gurufocus.com
- 5Medtronic's Sphere-9 catheter achieved an 87% acute success rate in a European ventricular tachycardia ablation analysis. news.medtronic.com
- 6Medtronic's PulseSelect system showed a 0.09% major complication rate in 1,160 global patients. massdevice.com
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.